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Detection of colonic cells in peripheral blood of
colorectal cancer patients by means of reverse
transcriptase and polymerase chain reaction
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Summary Circulating tumour cells play a central role in the metastatic process. but little is known about the relationship between this cellular
subpopulation and the development of secondary disease. This study was aimed at assessing the presence of colonic cells in peripheral
blood of patients with colorectal cancer in different evolutionary stages, by means of reverse transcriptase polymerase chain reaction (RT-
PCR) targeted to carcinoembryonic antigen (CEA) mRNA. In vitro sensitivity was established in a recovery experiment by preparing serial
colorectal cancer cell dilutions. Thereafter, 95 colorectal cancer patients and a control group including healthy subjects (n = 11). patients with
other gastrointestinal neoplasms (n = 11) or inflammatory bowel disease (n = 9) were analysed. Specific cDNA primers for CEA transcripts
were used to apply RT-PCR to peripheral blood samples. Tumour cells were detected down to five cells per 10 ml blood, thus indicating a
sensitivity limit of approximately one tumour cell per 107 white blood cells. CEA mRNA expression was detected in 39 out of 95 colorectal
cancer patients (41.1/o), there being a significant correlation with the presence of distant metastases at inclusion. None of the healthy
volunteers and only 1 of 11 patients (9.1%) with other gastrointestinal neoplasms had detectable CEA mRNA in peripheral blood. By contrast.
CEA mRNA was detected in five of the nine patients (55.6%) with inflammatory bowel disease. These results confirm that it is feasible to
amplify CEA mRNA in the peripheral blood, its presence being almost certainly derived from circulating malignant cells in colorectal cancer
patients. However, CEA mRNA detectable in blood of patients with inflammatory bowel disease suggests the presence of circulating non-
neoplastic colonic epithelial cells.
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The prognosis of patients w-ith malienant tumours is impaired
xxith metastatic dissemination of the disease. Despite adxances in
diagnostic and therapeutic approaches. 30-40% of patients w-ith
colorectal cancer undergoinc curative resection for primary
neoplasm dexelop local or distant tumour relapse during follow--
up. which carries a high probability of death (Borinc et al. 1993:
Safi and Bever. 1993).
Metastasis is a multistep process involving numerous
host-tumour interactions. in xAhich haematogenous spread of
cancer cells from the primary tumour constitutes a key point
(Liotta and Stetler-Stexenson. 1991). Investigations devoted to
studv this subpopulation of circulating, malignant cells have been
limited until the advent of the reverse transcriptase polI merase
chain reaction (RT-PCR) (Johnson et al. 1995). Usinc this
approach and targeting tissue-specific gene transcription. it has
been possible to identify circulatinc cancer cells in patients xxith
different neoplasms (Smith et al. 1991: Moreno et al. 1992: Tada
et al. 1993: Hillaire et al. 1994). including colorectal cancer
(Hardingham et al. 1995: Jonas et al. 1996: Denis et al. 1997:
Nakamori et al. 1997: Wonc et al. 1997).
With regard to the detection of circulating tumour cells in
colorectal cancer. sex-eral aspects need to be clarified. In that sense.
Received 17 November 1997
Revised
Accepted 1 Apnl 1998
Correspondence to: A Castells. Gastroenterology Department. Hospital
Clinic Provincial. Villarroel 170. 08036 Barcelona. Catalonia. Spain
the lack of an extensive control group (Denis et al. 1997: Nakamonr
et al. 1997: Wong et al. 1997) or the inclusion ofonlx patients wxith
colorectal lixer metastases (Jonas et al. 1996) preclude an appropri-
ated assessment ofboth accuracv ofthis method and the relationship
betx-een presence ofcirculating malignant cells and tumour stage.
The present study Aas aimed at assessinc the presence of
colonic cells in peripheral blood of colorectal cancer patients by
means of RT-PCR targeted to carcinoembryonic antigen (CEA)
mRNA. After confirming in vitro sensitixity- in a recoverx expen-
ment. a large series ofcolorectal cancer patients in different evolu-
tionarv stages and a control group includinc not onlv healthv
subjects but also patients with othergastrointestinal disorders were
analy sed. In this regard. inclusion of a subset of patients with
inflammatorx bowxel disease is especially noteworthx because it
represents a well-characterized non-neoplastic local injury.
Finallv. the effect of remoxing, the primarv tumour on circulating
neoplastic cells A-as also investigated in a subgroup of cases
submitted to surgical resection.
PATIENTS AND METHODS
Patients
Betx een October 1995 and September 1996. 95 consecutive
patients with histologically confirmed primary colorectal cancer
were included in the study. The median age wxas 69 y-ears (range
25-93x).with 60 men and 35 w-omen. According to the TNM system
(Intemational Union Against Cancer). six patients were classified
in stage I. 32 in stage II. 37 in stage III and 20 in stagye IV
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Table 1 Correlation between presence of CEA mRNA in peripheral bk)od
and baseline charactenstics of patients with colorectal cancer included in the
study
CEA mRNA posifive paenta (%) P-value
Age
<72 years 19/50 (38)
>72 years 20/45 (44) 0.52
Sex
Men 22/60 (37)
Women 17/35 (49) 0.25
Lymph node involvement-
Absent 17/48 (35)
Present 21141 (51) 0.13
Distant metastases
Absent 27/75 (36)
Present 12/20 (60) 0.05
TNM classification
2/6 (33)
11 12/32 (37)
III 13/37 (35) 0.28c
IV 12/20 (60)
Histological differentiation:
Well 5/8 (62)
Moderate 28172 (39) 0.31c
Poor 5/9 (56)
aResufts expressed as number of cases in which CEA mRNA was detectable
per total number of cases (percentage). nReferred to 89 patients submitted to
surgical resection, in whom histological examination was feasible. cP-value
for trend. CEA. carcinoembryonic antigen.
Control group subjects were recruited during, the same period of
time and included 11 healthv volunteers. nine patients with inflam-
matorv bowel disease (six of them with Crohn's disease and three
with ulcerative colitis) and 11 patients with other gastrointestinal
neoplasms (four aastric carcinomas. four pancreatic carcinomas.
one oesophageal cancer and two benign adenomatous polyps).
Peripheral venous blood samples (20 ml) were obtained with a
standard venepuncture technique using heparinized tubes. In
patients with colorectal cancer. the blood sample was collected
before any therapeutic procedure. Additionallv. in a subset of
patients submitted to surgical resection of the primary tumour. a
second sample was collected within 24 h of the intervention.
Therefore. only one blood sample was taken at each time point.
The protocol was approved by the institutional Ethics of
Research Committee and informed consent was obtained from
each patient.
Mononuclear cell isolation and RNA extraction
Mononuclear cells from peripheral blood samples were isolated
using a Ficoll gradient. Samples were firstly diluted with 30 ml of
phosphate-buffered saline (PBS) and then layered on 15 ml of
Ficoll gradient solution. They were centrifuged at 700g for
30 min. Mononuclear cells. localized in the interphase between
plasma and Ficoll. were collected and precipitated by centrifuga-
tion at 1000g for 10 min. Pellets obtained were washedtwice with
PBS. The specimens were stored at -80CC.
Total RNA extraction was performed according to the method of
Chirgwin et al. 1979. Because of the lack ofsignificant differences
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Figure 1 Schematic representation of human carcinoembryonic antigen
(CEA) gene. indicating the positions of oligonucleotide primers for CEA
mRNA detection. The PCR was performed using primers CNC1 and CNC2 to
obtain a 388-bp PCR product
between groups with regards to white blood cell count (data not
shown). this parameter wvas not taken into account in extractine
total R.NA.
Reverse transcriptase and polymerase chain reaction
Rexerse transcriptase (RT) reaction xwas prepared in a final volume
of 20 gl and contained 4 gl of total RNA. 4 pl of RT 5x buffer
(Tris-HCl 250 mmol 1-') pH 8.3. potassium chloride 250 mmol 1-1.
magnesium chloride 50 mmol 1-1. dithiothreitol (DTT)
50 mmol 1-'. spermidine 2.5 mmol 1-'). 1.5 tl magnesium chloride
(50 mmol 1-1. Gibco-BRL). 2 gi deoxynucleotide triphosphates
(dNTPs) (10 mmol 1-1 each). 1 gl random primer (500 gag ml-'.
Promeaa). 0.5 pg RNAsin (40 U ml-'. Promega). 5 PI distilled
water and 2 pl AMV (axvian mveloblastosis vinus) reverse tran-
scriptase (5 U ml-'. Promega). RT reaction was incubated at 42 C
for 45 min followed by a 5-min period at 95"C to inactix-ate the
rexerse transcriptase.
CEA-specific oligonucleotide primers xere synthesized
according, to published sequence information (Schrewe et al. 1990):
CNC1: 5'-TCCATCTCCAGCAACAACTCC-3' (sense) and CNC2:
5'-AAAGTCCCATTGACAAACCAA-3' (anti-sense). Primers
were selected to span an intron. to synthesize different-sized ampli-
fication products from the CEA mRNA (388 bp) and any contami-
nating genomic DNA (approximately 1020 bp). A schematic
representation ofthe CEA primer positions is shown in Fiaure 1.
RT solution (2.5 pg) was diluted in a final xolume of 50 gl of
PCR reaction mixture which contained 5 gl PCR lOx buffer (Tris-
HCI 200 mmol 1-' pH 8.4. potassium chloride 500 mmol 1-1).
1 pg d-NTPs (2 mmol 1-1 each). 2.5 gl of each CEA gene pnrmer
(20 jamol 1-'). 0.5 pg Taq polymerase (5 U ml-l. Gibco-BRL) and
distilled water to 50 p1. Samples were overlaid w-ith mineral oil
and then heated at 94°C for 3 min. Cycle conditions were: 94-C
for 30 s. 62-C for 1 min. 72°C for 1 mn. for 35 cycles. PCR was
completed with a penrod of5 mmn at 720C.
Samples were electrophoresed on 2%7 agarose gels and xisual-
ized bx ethidium bromide staining.
To ensure that bands correspond to CEA cDNA. a restriction
diaest usina enzymes PstI. HhaI and RsaI was performed.
Integrity of the RNA obtained from clinical samples wxas
confirmed by determining the presence of glyceraldehyde phos-
phate dehydrogenase (GAPDH) m_RNA in the same samples.
using pnmers GI: 5'-CCATGGAGAAGGCTGGGG-3' (sense)
and G2: 5'-CAAAGTTGTCATGGATGACC-3' (anti-sense).
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The study A-as performed in a blinded fashion. so that patients'
clinical characteristics were unknown by the investigator
performing RT-PCR on the blood samples. To ensure accurate
data. RT-PCR analysis Aas carried out in duplicate.
Recovery experiments
Tumour cells. from a surgically resected primary colorectal carci-
noma specimen. %vere obtained followinr a modified Ballet's
method (Ballet et al. 1984: Roberts et al. 1994). Briefly. colorectal
cancer tissue Awas embedded in a calcium-free buffer %varmed at
37zC (HEPES 10 mmol 1-1. sodium chloride 137 mmol 1-'. potas-
sium chloride 2.68 mmol 1-1. disodium hydrogen phosphate
0.7 mmol 1-'. glucose 10 mmol 1-'. EGTA 0.5 mmol 1-'. pH 7.45).
Tissue w-as carefully minced and fragments incubated in buffer
containing collacenase IV (Sigma). This suspension was filtered
through a sterile gauze and then centrifuged at 100 g for 5 mmn.
Tissue fraaments retained by the gauze were once again incubated
in collagenase buffer and filtered. The resulting, pellets were resus-
pended in RPMI-1640 medium with 25 mmol 1-1 HEPES buffer
and L-glutamine (Gibco-BRL) at 37C for 10 mn. To remove
medium. cells were washed t-ice with a phosphate buffer (potas-
sium chloride 2.68 mmol 1-'. potassium dihydrogen phosphate
1.5 mmol 1-1. disodium hydrogen phosphate 8.45 mmol 1-'. sodium
chloride 137 mmol 1-'. pH 7.4) and resulting cells were counted
and tested for Xiability. Cell density Aas calculated to be approxi-
mately 5000 cells g1-'.
Serial colorectal cancer cell dilutions A-ere prepared and mixed
with %-hole blood samples from the same patient to obtain concen-
trations ofneoplastic cells of5000. 500. 50. 25 and 5 per 10 ml. A
further blood sample with no tumour cells was used as a control.
Statistical methods
Continuous variables w-ere expressed as medians ± standard devia-
tions. For statistical analysis. age was dichotomized at the median.
Differences in relative frequency of detected circulating colonic
cells and correlation be-tween qualitatixe variables were evaluated
by means of the X test. applying the Yates' correction when
needed. Continuous variables with non-parametric distribution
w%vere compared by means ofthe Mann-Whitney U-test.
RESULTS
Recovery experiments
Tumour cells from a surgically resected colon carcinoma specimen
,-ere detected down to 5 cells per 10 ml blood by RT-PCR forCEA
mRNA. This indicates a sensitixity limit of approximately one
tumour cell per 10- white blood cells. There w-as an increase in
band intensity ith increasing amounts of RNA. and no transcripts
A ere identified in the negati'e control sample (Figure 2).
CEA mRNA from clinical samples
CEA mRNA was detected in the peripheral blood samples from 39
out of 95 colorectal cancer patients (41.1%). probably indicating
the presence ofcirculating neoplastic cells. According to the TNM
classification. the frequency of positive cases w-as: tu-o out of six
patients (33%c) in stage I. 12 of 32 patients (37.5%7c) in stage II. 13
of 37 patients (35.1%- ) in stage III. and 12 of 20 patients (60%(7) in
stage IV. Correlation between CEA mRNA expression in penrph-
eral blood and baseline characteristics of patients with colorectal
cancer is depicted in Table 1. As shown. CEA mRNA positivitv
significantly correlated with the presence of distant metastases at
inclusion [presence: 12/20 (60%e ) vs absence: 27/75 (36%- ):
P = 0.05]. In addition. serum CEA levels in patients xxith CEA
mRNA positivity (73 ± 283 ng ml- ) were significantly higher than
in those patients with negative expression (38 ± 179 ng ml-') (LT-
value: 476: P < 0.02).
In contrast. none of the healthy volunteers and only 1 of 11
patients (9.1 %7c) with other aastrointestinal neoplasms had detectable
CEA mRNA in peripheral blood. By contrast. CEA mRNA was
detected in five of the nine patients (55.6%7) with inflammators
bowel disease (Figure 3). These positixe control subjects included
one patient with aastric cancer. one patient with ulcerative colitis
and four patients w-ith Crohn's disease respectixely.
Finallv. in a non-selected subgroup of 24 CEA inRNA-positive
patients submitted to surgical resection of the primary tumour.
persistence of CEA mRNA expression was observed in 15 cases
wxithin 24 h after the intervention. Moreover. the prevalence of
persistent CEA mRNA positixvity was higher in patients with
lymph node involvement and/or distant metastasis at surgery than
A
Figure 2 Detecion of CEA mRNA in 10 ml of normal blood sample spiked
with dilutions of isolated colorectal cancer cells (recovery experiment).
Electrophoresis on 20/o agarose gel, followed by ethidium bromide staining.
There was an increase in the intensity of the 388-bp band with increasing
mRNA concentration. WM. molecular weight marker V: C+. positive control:
C-. negative control
Figure 3 Detecton of CEA mRNA in peripheral bklod of colorectal cancer
patients and control subjects. Electrophoresis on 20/o agarose gel, followed
by ethidium bromide staining. RT-PCR products for GAPDH of the same
RNA samples were identfied as a 169-bp band. (A) WM, molecular weight
marker V; C+. positive control; 1-4, positve colorectal cancer patients; 5 and
6. negative colorectal cancer patients. (B) WM, molecular weight marker V: 7
and 8. positive control patients (inflammatory bowel disease): 9 and 10,
negative control patients (gastnc and pancreatic carcinormas); 11 and 12.
negative control subjects (healthy volunteers): C-, negative control
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in those in whom neoplastic dissemination was ruled out [12/17
(71%) vs 3n (43%) respectively; P = 0.1].
All cases demonstrated satisfactory RNA quality by a control
PCR amplification of GADPH mRNA (Figure 3). No inconsistent
results were obtained when repeating the analysis in the same
sample.
DISCUSSION
The results of the present study confirm that CEA mRNA can be
detected in the peripheral blood of patients with colorectal carci-
noma by means of RT-PCR. In this setting, the detection of CEA
mRNA is very probably associated with the presence of circu-
lating tumour cells on the basis of the following considerations:
(1) the frequency ofCEA mRNA positivity correlated with tumour
stage; (2) CEA mRNA expression disappeared after surgical
resection of the primary tumour in most of the non-metastatic
colorectal cancer patients; (3) serum CEA concentration correlated
with CEA mRNA positivity; and (4) healthy volunteers had
undetectable CEA mRNA in the blood. Additionally. the recovery
experiment indicated a clear correlation between CEA mRNA
expression and tumour cell concentration. In this regard, although
it cannot be assumed that the detection threshold in all clinical
samples was identical to that in the recovery assay (O'Sullivan et
al, 1995), results obtained in colorectal cancer patients and healthy
volunteers indicate that specificity of our approach seems to be
adequate for its purpose. Nevertheless, false-negative results could
not be definitively ruled out.
Several reports have demonstrated that PCR is a useful tool for
the detection ofcirculating cancer cells in solid tumours (Johnson
et al, 1995). In gastrointestinal tumours, in which cancer-specific
mutations in DNA have not yet been found, it is necessary to use
reverse transcriptase to prepare cDNA from peripheral blood
mRNA for identifying tissue-specific gene expression. Detection
of occult neoplastic cells in patients with colorectal cancer has
been carried out using different targets. K-ras mutations have been
reported as a useful marker when samples ofthe primary tumour
are available to confirm the mutation (Hardingham et al, 1995).
Cytokeratins, a multigene family of proteins with differentiation-
associatedpatterns ofexpression (Moll et al, 1982), have also been
used to characterize neoplastic cells of epithelial origin in bone
marrow (Lindemann et al. 1992) andperipheral blood (Denis et al,
1997; Nakamori et al, 1997; Soeth et al, 1997). However, most of
them (CK-8, CK-18 and CK-19) are found in samples of healthy
subjects, thus limiting their suitability as targets (Burchill et al,
1995). CEA was chosen as a target because it is a cell-surface
molecule constitutively expressed in the colonic epithelial tissue.
and its expression is maintained in almost all colorectal carci-
nomas (Shively and Beatty, 1985). Its genomic organization
(Schrewe et al, 1990) and cDNA sequence (Oikawa et al, 1987)
are known. In addition, this target has been used in the specific
detection of CEA-expressing tumour cells in bone marrow aspi-
rates (Gerhard et al, 1994) and, recently, in the identification of
circulating neoplastic cells in patients with colorectal liver metas-
tasis (Jonas et al, 1996).
From a clinical point ofview, the present study documents limi-
tations on both the sensitivity as well as the specificity ofthe assay,
thus probably restricting the diagnostic usefulness ofthis technique
in colorectal cancer. In that sense, CEA mRNAcouldbedetected in
patients withotergastrointestinal neoplasms expressing CEA as it
was expected, and in those with inflammatory bowel disease. By
contrast, not all colorectal cancer patients, including those with
stage IV disease. had detectable CEA mRNA expression. This fact
probably reflects that tumour cells are circulating in clusters (Liotta
and Stetler-Stevenson, 1991). thus favouring a bias in the collection
ofblood samples. According to this suggestion. the true prevalence
of circulating cancer cells is likely to be much higher than that
detected by a single blood extraction.
In contrast, the presence of circulating tumour cells is expected
to be associated with a poor prognosis (Hardingham et al, 1995).
in a similar manner to micrometastatic tumour cells in bone
marrow (Lindemann et al. 1992; Soeth et al, 1997). Results of the
present investigation suggest that circulating neoplastic cells
correlate with the presence of distant metastasis at inclusion.
However, it should be emphasized that a high proportion of non-
metastatic colorectal cancer patients (stages I-HI) were positive
for CEA mRNA expression, even after surgery. Then, clinical rele-
vance of this finding remains uncertain at present. Considering
metastasis is believed to be an inefficient process (Liotta and
Stetler-Stevenson, 1991), evidence of circulating tumour cells
could represent an irrelevant clinical event. On the contrary. if
their presence had prognostic implications, detection ofmalignant
cells in peripheral blood may improve tumour staging and help to
identify those patients who would benefit from systemic therapy
after surgery. Accordingly, the presence ofcirculating cancer cells
should be considered either as a marker of metastatic potential or
evidence of residual disease, and redefinition of remission status
could be needed. Long-term follow-up ofthese patients will allow
us to establish its clinical relevance.
In the present study, a significant proportion of patients with
inflammatory bowel disease had detectable CEA mRNA expres-
sion in the blood, the significance of this finding being unclear.
Illegitimate transcription by white blood cells or epithelial conta-
mination of samples with a small number of skin cells because of
the venepuncture cannot be formally excluded, but the absence of
expression in healthy subjects made this possibility very unlikely.
Circulating CEA mRNA caused by cytolysis is improbable
because of large amounts of RNAases (Hillaire et al, 1994).
Although up-regulation ofCEA gene family members in granulo-
cytes of patients with inflammatory bowel disease has not been
described yet, the feasibility ofthishypothesis cannotbe ruled out.
However, considering that this disease involves necrosis of the
colonic epithelium, CEA mRNA expression suggests the presence
of non-neoplastic epithelial colonic cells in peripheral blood. A
similar event has been shown among patients with non-malignant
disease submitted to surgical resection or liver transplantation in
whom peripheral alpha-fetoprotein mRNA expression was
detected after surgery (Lemoine et al, 1997). Unfortunately. the
low sensivity of both direct microscopy and immunocyto-
chemistry in this setting (Leather et al, 1993; Wong et al, 1995)
precludes the distinction ofboth cellularsubtypes and, therefore, a
definitive assessment of the origin of CEA mRNA expression in
patients with inflammatory bowel disease.
In summary, the results ofthe present investigation confirm that
it is possible to amplify CEA mRNA in the peripheral blood, its
presence in colorectal cancer patients being almost certainly
derived from circulating neoplastic cells. Correlation of this
cellular subpopulation with the occurrence ofdistant metastasis at
inclusion suggests a possible role of this method in improving
cancer staging. Nevertheless, CEA mRNA detectable in blood of
patients with inflammatory bowel disease probably indicates the
presence of non-neoplastic epithelial colonic cells. Therefore.
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CEA mRNA expression would indicate the loss ofcell adhesion in
colonic epithelium because of either neoplastic or inflammatory
processes.
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